Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,472.00
Bid: 12,492.00
Ask: 12,496.00
Change: 74.00 (0.60%)
Spread: 4.00 (0.032%)
Open: 12,432.00
High: 12,526.00
Low: 12,318.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London midday: Homebuilders knocked lower by remarks from Carney

Tue, 14th Jul 2015 13:09

(ShareCast News) - Bank of England Governor Mark Carney told the Treasury Select Committee Bank Rate may be headed higher a little bit sooner than markets anticipated, sending stocks - especially homebuilders - listed on the second tier index promptly lower.As of 12:13 the top flight index was off by 19.22 points to 6,718.36 and the FTSE 250 lower by a hefty 141.80 points to 17,567.33.In testimony to the Committee Carney said that, "the point at which interest rates may begin to rise is moving closer given the performance of the economy."That sent the yield on the benchmark 10-year Gilt higher by four basis points to 2.15% and saw the pound snap higher towards 1.56 versus the US dollar."We judge these comments as supporting our view that the Bank is likely to deliver the first rate hike earlier than the current market pricing of May 2016. Our forecast is for a February 2016 move," economists at BNP Paribas said in a research report e-mailed to clients.Subdued core inflation in the UKHis remarks came after the latest CPI figures from ONS revealed that core inflation in the UK slipped a tad in June, to a 0.8% year-on-year pace after a reading of 0.9% in May - the joint lowest print since March 2001.Nevertheless, "this weakness continues to largely reflect cheaper goods imports. Inflation in the services sector, while below its average of 3.5% over the last decade, was a much stronger 2.2%," Samuel Tombs, Senior UK economist at Capital Economics pointed out.The headline consumer price index was flat versus a year ago, after a rise of just 0.1% in May, as expected by economists."We believe it is most likely that consumer price inflation will hover around zero through the summer and then start heading gradually but decisively up from September. There is obviously the risk that there could be another very brief dip into deflation if oil prices extend their current softening," Dr.Howard Archer, chief UK+European economist at IHS Global Insight explained to clients.All eyes on AthensActing as a backdrop, all eyes were on the parliament in Athens and whether it approve the list of reforms asked of it by creditors.That came amid an urgent need for fresh funds by Greece to meet a 20 July payment of €3.5bn falling due to the European Central Bank and to recapitalise the country's banks and restore the flow of credit in the economy."Capital control implementation can be swift, but its full removal is a lengthy process," Goldman Sachs told clients, adding that a normally functioning banking sector could be expected immediately.Defence sector finds a bidShares in defence and aerospace engineer Meggitt rose on Tuesday following a report in the Financial Times that a merger with Cobham might be on the cards. Atif Latif, director of trading at Guardian Stockbrokers, said he sees the rationale of a tie-up between the two as a defence play.Analysts at Deutsche Bank upgraded their rating for Sky from 'hold' to 'buy' and raised estimates for 2017 by 20% more than consensus. In a note to clients, Deutsche Bank said the FTSE 250 firm was the best positioned in Europe to capitalise on growth areas related to online video.Shares in homebuilders such as Taylor Wimpey, Barratt Developments and Persimmon were all knocked lower by Carney's remarks.AstraZeneca's Iressa drug, which is used in the treatment of metastatic non-small cell lung cancer (NSCLC), has been approved by the US Food and Drug Administration.Iressa is approved in 91 countries for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor mutation-positive NSCLC, which is the most common type of lung cancer.Miner BHP Billiton reported that director Sir John Buchanan died on Monday, having served on the board from 2003 up until the time of his death. Buchanan, who was the senior independent director of Anglo-Australian giant, "provided wise counsel to his fellow directors and to management, and made an invaluable contribution to BHP Billiton," said chairman Jac Nasser.Market MoverstechMARK 3,173.01 -0.20%FTSE 100 6,717.31 -0.31%FTSE 250 17,563.25 -0.82%FTSE 100 - RisersSky (SKY) 1,113.00p +3.25%Meggitt (MGGT) 478.40p +1.68%Reed Elsevier (REL) 1,095.00p +0.92%International Consolidated Airlines Group SA (CDI) (IAG) 553.50p +0.82%Unilever (ULVR) 2,904.00p +0.80%British American Tobacco (BATS) 3,642.00p +0.69%Carnival (CCL) 3,494.00p +0.60%Lloyds Banking Group (LLOY) 85.76p +0.54%Morrison (Wm) Supermarkets (MRW) 178.80p +0.45%Hikma Pharmaceuticals (HIK) 2,073.00p +0.34%FTSE 100 - FallersTaylor Wimpey (TW.) 185.80p -3.18%Barratt Developments (BDEV) 624.00p -2.73%Persimmon (PSN) 1,967.00p -2.33%Weir Group (WEIR) 1,587.00p -2.22%GKN (GKN) 317.70p -2.10%TUI AG Reg Shs (DI) (TUI) 1,066.00p -1.93%Aberdeen Asset Management (ADN) 401.30p -1.91%Johnson Matthey (JMAT) 3,003.00p -1.54%Pearson (PSON) 1,231.00p -1.52%Marks & Spencer Group (MKS) 539.50p -1.46%FTSE 250 - RisersInternational Personal Finance (IPF) 363.30p +3.03%Evraz (EVR) 121.00p +2.89%Centamin (DI) (CEY) 59.90p +1.53%AO World (AO.) 133.20p +1.52%Greggs (GRG) 1,146.00p +1.42%NMC Health (NMC) 810.50p +1.31%Carillion (CLLN) 356.30p +1.31%Pace (PIC) 372.00p +1.20%Laird (LRD) 365.10p +1.11%Telecom Plus (TEP) 1,055.00p +1.05%FTSE 250 - FallersDrax Group (DRX) 248.50p -5.08%Tullow Oil (TLW) 288.80p -4.47%Hiscox Limited (CDI) (HSX) 869.00p -3.87%Man Group (EMG) 151.70p -3.80%Bellway (BWY) 2,304.00p -3.52%Hunting (HTG) 518.50p -3.36%Bovis Homes Group (BVS) 1,116.00p -3.21%Berkeley Group Holdings (The) (BKG) 3,258.00p -2.78%Just Retirement Group (JRG) 173.10p -2.75%Paragon Group Of Companies (PAG) 384.10p -2.61%
More News
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.